Free Trial
NASDAQ:XAIR

Beyond Air Q1 2025 Earnings Report

Beyond Air logo
$0.18 0.00 (-1.17%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$0.18 +0.00 (+0.06%)
As of 06/13/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beyond Air EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.12
One Year Ago EPS
-$0.45

Beyond Air Revenue Results

Actual Revenue
$0.68 million
Expected Revenue
$0.72 million
Beat/Miss
Missed by -$40.00 thousand
YoY Revenue Growth
N/A

Beyond Air Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Tuesday, August 6, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Beyond Air's Q4 2025 earnings is scheduled for Tuesday, June 17, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Beyond Air Earnings Headlines

Beyond Air (XAIR) to Release Quarterly Earnings on Tuesday
Banks aren’t ready for this altcoin—are you?
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.
Beyond Air granted U.S. patent for gaseous nitric oxide delivery
See More Beyond Air Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Beyond Air? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beyond Air and other key companies, straight to your email.

About Beyond Air

Beyond Air (NASDAQ:XAIR) operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

View Beyond Air Profile

More Earnings Resources from MarketBeat